Salicylic Acid Composition for Recurrent UTI Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for urinary tract infections (UTIs), particularly those caused by E. coli, often lead to antibiotic resistance and do not effectively prevent recurrence.

Innovation Solution

The use of salicylic acid and its metabolites, combined with oenothein B and extracts from Filipendula ulmaria and Epilobium parviflorum, which are administered orally to prevent or treat UTIs by inhibiting E. coli adhesion, growth, and providing diuretic effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to treat UTIs, then bacterial infection is eliminated, but antibiotic resistance emerges and recurrence is not prevented

Engineering Contradiction:

Improveinfection eliminationVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the anti-infectious action into multiple independent targets: anti-adhesion activity (preventing bacterial attachment to urothelial cells), bactericidal activity (killing bacteria directly), and diuretic activity (increasing urine flow to flush bacteria). This multi-target approach prevents resistance development by not relying on a single mechanism like traditional antibiotics.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The composition provides multi-functionality by combining compounds that perform multiple roles: salicylic acid and its metabolites provide both anti-adhesion and bactericidal effects, while oenothein B and Epilobium extracts contribute additional bactericidal and anti-inflammatory activities. This universal approach addresses infection prevention, treatment, and recurrence reduction simultaneously.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If single-target anti-infectious drugs are used, then specific bacterial enzymes are inhibited, but resistance mechanisms are triggered

Engineering Contradiction:

Improveenzyme inhibitionVSAvoidresistance mechanisms

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention divides anti-infectious protection into separate functional components: anti-adhesion compounds (salicylic acid derivatives) prevent bacterial attachment, while bactericidal compounds (oenothein B, Epilobium extracts) kill bacteria directly. This segmentation ensures that bacteria cannot develop resistance to all mechanisms simultaneously.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention uses a composite formulation combining multiple chemical compounds with different mechanisms of action: salicylic acid (anti-adhesion), its metabolites (bactericidal), oenothein B (bactericidal), and Epilobium extracts (anti-inflammatory and bactericidal). This composite approach creates synergistic effects that prevent resistance development.

Inventive Principle:

Principle #40Composite materials

3Productivity

If epithelial cells are exfoliated to clear E. coli, then infection is partially cleared, but host cells are damaged and incomplete clearance leads to persistent infection

Engineering Contradiction:

Improvebacterial clearanceVSAvoidhost cell damage

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The invention applies preliminary anti-adhesion action by using salicylic acid and its metabolites to prevent E. coli from attaching to urothelial cells in the first place. By blocking adhesion beforehand, the need for aggressive exfoliation is reduced, preventing host cell damage while still achieving bacterial clearance through gentler mechanisms.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention introduces intermediary compounds that mediate between the host and pathogen: salicylic acid derivatives act as intermediaries that block bacterial adhesion without requiring direct contact between bacteria and host cells, thereby preventing infection establishment while preserving host cell integrity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach demonstrates significant anti-adhesion and bactericidal effects against E. coli, reducing UTI symptoms and recurrence, while also offering a non-antibiotic alternative that may help mitigate antibiotic resistance.

Implementation Method 1

salicylic acid and some of its metabolites formed in vivo after ingestion of salicylic acid have a beneficial activity against E. coli bacteria adhesion on bladder cells

Methodology Applied

Scientific EffectAnti-adhesion effect:

Implementation Method 2

salicylic acid and some of its metabolites formed in vivo after ingestion of salicylic acid have a beneficial activity against E. coli bacteria adhesion on bladder cells but also a bactericidal effect

Methodology Applied

Scientific EffectBactericidal effect:

Implementation Method 3

oenothein B and extracts of Epilobium parviflorum containing oenothein B play a role on the inhibition on E. coli growth in vivo

Methodology Applied

Scientific EffectAntimicrobial effect:

Implementation Method 4

Methodology Applied

Scientific EffectDiuretic effect:

Data Source

PatentUS20250152609A1Salicylic acid compositions and uses thereof

Publication Date: 2025.05.15 PHARMALP SA

AI summary

The present invention is directed to compounds, compositions, uses and methods useful in the prevention or treatment of urinary infections, in particular E. coli infections and in particular recurrent urinary infections.